CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice

Richard M. Tempero, Michelle L. VanLith, Keita Morikane, Gerald J. Rowse, Sandra J Gendler, Michael A. Hollingsworth

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

A C57BL/6 mouse transgenic for human MUC1 (MUC1·Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1·Tg mice, challenged with syngeneic tumors expressing MUC1 (B16·MUC1), developed progressively growing MUC1-positive tumors, whereas wild-type C57BL/6 (wt) mice developed MUC1-negative tumors at a significantly slower rate. The results of a limiting dilution CTL frequency assay were not informative, in that similar numbers of MUC1-specific CTL precursors (CTL) were detected in MUC1·Tg and wt mice. Tumor immunity in vivo was characterized by an adoptive transfer method to evaluate the degree of MUC1 or non-MUC1 tumor immunity in wt or MUC1·Tg mice. The results revealed that wt mice developed protective tumor immunity mediated by MUC1-specific CD4+ lymphocytes, while MUC1·Tg mice were functionally tolerant to MUC1 in vivo. The potential of adoptive immunotherapy to provide immunity to tumors expressing MUC1 and to produce undesirable autoimmunity in recipient MUC1·Tg mice expressing MUC1 as a self Ag was evaluated. Adoptive transfer of immune cells from wt mice primed in vivo with B16·MUC1 tumor cells into MUC1·Tg recipients resulted in significant increases in the survival of MUC1·Tg recipients compared with unmanipulated control MUC1·Tg mice challenged with B16·MUC1 tumor cells. This response was specific for MUC1 since control tumors developed at equivalent rates in recipient or control MUC1·Tg mice. No gross or histologic evidence of autoimmunity was observed in recipient MUC1·Tg mice, indicating that tumor immune responses mediated by MUC1-specific CD4+ lymphocytes spare nontransformed epithelia-expressing MUC1.

Original languageEnglish (US)
Pages (from-to)5500-5506
Number of pages7
JournalJournal of Immunology
Volume161
Issue number10
StatePublished - Nov 15 1998

Fingerprint

Transgenic Mice
Immunity
Lymphocytes
Neoplasms
Adoptive Transfer
Autoimmunity
In Vitro Techniques
Adoptive Immunotherapy
Inbred C57BL Mouse
Epithelium
Survival

ASJC Scopus subject areas

  • Immunology

Cite this

Tempero, R. M., VanLith, M. L., Morikane, K., Rowse, G. J., Gendler, S. J., & Hollingsworth, M. A. (1998). CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Journal of Immunology, 161(10), 5500-5506.

CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. / Tempero, Richard M.; VanLith, Michelle L.; Morikane, Keita; Rowse, Gerald J.; Gendler, Sandra J; Hollingsworth, Michael A.

In: Journal of Immunology, Vol. 161, No. 10, 15.11.1998, p. 5500-5506.

Research output: Contribution to journalArticle

Tempero, RM, VanLith, ML, Morikane, K, Rowse, GJ, Gendler, SJ & Hollingsworth, MA 1998, 'CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice', Journal of Immunology, vol. 161, no. 10, pp. 5500-5506.
Tempero, Richard M. ; VanLith, Michelle L. ; Morikane, Keita ; Rowse, Gerald J. ; Gendler, Sandra J ; Hollingsworth, Michael A. / CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. In: Journal of Immunology. 1998 ; Vol. 161, No. 10. pp. 5500-5506.
@article{97653f4ce37246fe9cf446295dc22906,
title = "CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice",
abstract = "A C57BL/6 mouse transgenic for human MUC1 (MUC1·Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1·Tg mice, challenged with syngeneic tumors expressing MUC1 (B16·MUC1), developed progressively growing MUC1-positive tumors, whereas wild-type C57BL/6 (wt) mice developed MUC1-negative tumors at a significantly slower rate. The results of a limiting dilution CTL frequency assay were not informative, in that similar numbers of MUC1-specific CTL precursors (CTL) were detected in MUC1·Tg and wt mice. Tumor immunity in vivo was characterized by an adoptive transfer method to evaluate the degree of MUC1 or non-MUC1 tumor immunity in wt or MUC1·Tg mice. The results revealed that wt mice developed protective tumor immunity mediated by MUC1-specific CD4+ lymphocytes, while MUC1·Tg mice were functionally tolerant to MUC1 in vivo. The potential of adoptive immunotherapy to provide immunity to tumors expressing MUC1 and to produce undesirable autoimmunity in recipient MUC1·Tg mice expressing MUC1 as a self Ag was evaluated. Adoptive transfer of immune cells from wt mice primed in vivo with B16·MUC1 tumor cells into MUC1·Tg recipients resulted in significant increases in the survival of MUC1·Tg recipients compared with unmanipulated control MUC1·Tg mice challenged with B16·MUC1 tumor cells. This response was specific for MUC1 since control tumors developed at equivalent rates in recipient or control MUC1·Tg mice. No gross or histologic evidence of autoimmunity was observed in recipient MUC1·Tg mice, indicating that tumor immune responses mediated by MUC1-specific CD4+ lymphocytes spare nontransformed epithelia-expressing MUC1.",
author = "Tempero, {Richard M.} and VanLith, {Michelle L.} and Keita Morikane and Rowse, {Gerald J.} and Gendler, {Sandra J} and Hollingsworth, {Michael A.}",
year = "1998",
month = "11",
day = "15",
language = "English (US)",
volume = "161",
pages = "5500--5506",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice

AU - Tempero, Richard M.

AU - VanLith, Michelle L.

AU - Morikane, Keita

AU - Rowse, Gerald J.

AU - Gendler, Sandra J

AU - Hollingsworth, Michael A.

PY - 1998/11/15

Y1 - 1998/11/15

N2 - A C57BL/6 mouse transgenic for human MUC1 (MUC1·Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1·Tg mice, challenged with syngeneic tumors expressing MUC1 (B16·MUC1), developed progressively growing MUC1-positive tumors, whereas wild-type C57BL/6 (wt) mice developed MUC1-negative tumors at a significantly slower rate. The results of a limiting dilution CTL frequency assay were not informative, in that similar numbers of MUC1-specific CTL precursors (CTL) were detected in MUC1·Tg and wt mice. Tumor immunity in vivo was characterized by an adoptive transfer method to evaluate the degree of MUC1 or non-MUC1 tumor immunity in wt or MUC1·Tg mice. The results revealed that wt mice developed protective tumor immunity mediated by MUC1-specific CD4+ lymphocytes, while MUC1·Tg mice were functionally tolerant to MUC1 in vivo. The potential of adoptive immunotherapy to provide immunity to tumors expressing MUC1 and to produce undesirable autoimmunity in recipient MUC1·Tg mice expressing MUC1 as a self Ag was evaluated. Adoptive transfer of immune cells from wt mice primed in vivo with B16·MUC1 tumor cells into MUC1·Tg recipients resulted in significant increases in the survival of MUC1·Tg recipients compared with unmanipulated control MUC1·Tg mice challenged with B16·MUC1 tumor cells. This response was specific for MUC1 since control tumors developed at equivalent rates in recipient or control MUC1·Tg mice. No gross or histologic evidence of autoimmunity was observed in recipient MUC1·Tg mice, indicating that tumor immune responses mediated by MUC1-specific CD4+ lymphocytes spare nontransformed epithelia-expressing MUC1.

AB - A C57BL/6 mouse transgenic for human MUC1 (MUC1·Tg) was developed to evaluate MUC1-specific tumor immunity in an animal that expresses MUC1 as a normal self protein. Previous studies showed that MUC1·Tg mice, challenged with syngeneic tumors expressing MUC1 (B16·MUC1), developed progressively growing MUC1-positive tumors, whereas wild-type C57BL/6 (wt) mice developed MUC1-negative tumors at a significantly slower rate. The results of a limiting dilution CTL frequency assay were not informative, in that similar numbers of MUC1-specific CTL precursors (CTL) were detected in MUC1·Tg and wt mice. Tumor immunity in vivo was characterized by an adoptive transfer method to evaluate the degree of MUC1 or non-MUC1 tumor immunity in wt or MUC1·Tg mice. The results revealed that wt mice developed protective tumor immunity mediated by MUC1-specific CD4+ lymphocytes, while MUC1·Tg mice were functionally tolerant to MUC1 in vivo. The potential of adoptive immunotherapy to provide immunity to tumors expressing MUC1 and to produce undesirable autoimmunity in recipient MUC1·Tg mice expressing MUC1 as a self Ag was evaluated. Adoptive transfer of immune cells from wt mice primed in vivo with B16·MUC1 tumor cells into MUC1·Tg recipients resulted in significant increases in the survival of MUC1·Tg recipients compared with unmanipulated control MUC1·Tg mice challenged with B16·MUC1 tumor cells. This response was specific for MUC1 since control tumors developed at equivalent rates in recipient or control MUC1·Tg mice. No gross or histologic evidence of autoimmunity was observed in recipient MUC1·Tg mice, indicating that tumor immune responses mediated by MUC1-specific CD4+ lymphocytes spare nontransformed epithelia-expressing MUC1.

UR - http://www.scopus.com/inward/record.url?scp=0032533812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032533812&partnerID=8YFLogxK

M3 - Article

C2 - 9820526

AN - SCOPUS:0032533812

VL - 161

SP - 5500

EP - 5506

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -